Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
US FDA Recalibrates Office Of Generic Drugs
As Part Of Wider Structural Changes To CDER
Jan 11 2021
•
By
David Wallace
The FDA is reorganizing the Office of Generic Drugs • Source: Shutterstock
(Sarah Silbiger/Getty Images)
More from Regulation
More from Policy & Regulation